Study of Adding or Not Liposomal Transcrocetin (L-TC) With Concomitant HypoFractionated Radiation ThErapy and TEmozolomide in Newly Diagnosed GLioblastoma (GBM) Patients

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

554

Participants

Timeline

Start Date

January 1, 2025

Primary Completion Date

December 31, 2032

Study Completion Date

December 31, 2032

Conditions
Glioblastoma
Interventions
DRUG

Administration of L-TC

"Administration of L-TC (300 mg) as an IV perfusion, before each radiotion session~Radiotherapy : delivered at 40.5 Gy in 15 fractions of 2.7 Gy - One fraction a day 5 fractions per week~\+ Temozolomide delivered at a dose of 75 mg per square meter per day, given 7 days per week from the first day of radiotherapy until the last day of radiotherapy, but for no longer than 25 days."

OTHER

Radiotherapy plus Temozolomide

"Radiotherapy : delivered at 40.5 Gy in 15 fractions of 2.7 Gy - One fraction a day 5 fractions per week~\+ Temozolomide delivered at a dose of 75 mg per square meter per day, given 7 days per week from the first day of radiotherapy until the last day of radiotherapy, but for no longer than 25 days."

Trial Locations (1)

67033

Institut de cancérologie Strasbourg Europe, Strasbourg

All Listed Sponsors
collaborator

LEAF4Life, Inc.

INDUSTRY

lead

Institut de cancérologie Strasbourg Europe

OTHER